Faraday Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.faradaypharma.com
Evaluation in STEMI Patients Using FDY-5301
Phase 3
Active, not recruiting
- Conditions
- STEMIPercutaneous Coronary RevascularizationAcute Myocardial Infarction
- Interventions
- Other: Placebo
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 2351
- Registration Number
- NCT04837001
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸Allina Health System, Minneapolis, Minnesota, United States
Evaluation of FDY-5301 in Major Trauma Patients in ICU
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04430283
- Locations
- 🇺🇸
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Harborview, Seattle, Washington, United States
A Study of Acute Myocardial Infarction Using FDY-5301
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03470441
- Locations
- 🇭🇺
Budai Irgalmasrendi Kórház, Budapest, Hungary
🇭🇺Magyar Honvédség Egészségügyi Központ, Budapest, Hungary
🇭🇺Borsod-Abaúj-Zemplén Megyei Központi Kórház, Miskolc, Hungary
© Copyright 2025. All Rights Reserved by MedPath